MedTrace Logo

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

NCT00713336 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-09-28

No results posted yet for this study

Summary

This Study compares two ZD4054 (Zibotentan) doses (10mg and 30mg) with a placebo and a positive control to look at ZD4054 (Zibotentan)'s effect on the ECG of Healthy Volunteer

Conditions

  • Healthy

Interventions

DRUG

ZD4054

ZD4054 10mg Tablet

DRUG

Moxifloxacin

400 mg capsule

DRUG

ZD4054 Placebo

3 tablets

DRUG

Moxifloxacin placebo

1 capsule

DRUG

ZD4054 Placebo

2 tablets

DRUG

ZD4054

30mg tablet

DRUG

ZD4054

10mg tablet

Sponsors & Collaborators

Principal Investigators

  • Raj Chetty, MD · Clinical Pharmacology UnitAlderley ParkAstraZenecaMacclesfieldSK10 4TG

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Completion
2008-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713336 on ClinicalTrials.gov